During the past decade, Paediatric Oncology and Haematology Offices, conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Paediatric Oncology and Haematology Offices," are "Ependymoma" (1 trials) and "Recurrent or Refractory Pediatric Ependymoma" (1 trials). Many other conditions were trialed in "Paediatric Oncology and Haematology Offices," in a lesser frequency.

Most popular intervention types in "Paediatric Oncology and Haematology Offices," are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Erlotinib" (1 trials), "erlotinib" (1 trials) and "etoposide" (1 trials). Other intervention names were less common.

The vast majority of trials in "Paediatric Oncology and Haematology Offices," are 2 trials for "All" genders.

Currently, there are NaN active trials in "Paediatric Oncology and Haematology Offices,". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Paediatric Oncology and Haematology Offices,, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Paediatric Oncology and Haematology Offices,, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".